前哨淋巴结病理超分期:SENTIX前瞻性国际研究在早期宫颈癌患者中的最终结果
SENTIX是一项国际前瞻性试验,纳入T1a1/LVSI+至T1b2、常见病理类型、影像学无可疑淋巴结且双侧前哨淋巴结(SLN)检出的宫颈癌患者,采用强化超分期方案(石蜡块按150μm间隔/层面完整切片)并集中质控。647例可评估患者中12.5%(81/647)为淋巴结阳性N1;术中检出46/81(56.8%),超分期额外发现43.2%(35/81)的转移。作者认为检查4个层面可检出>90%的N1患者,是国际标准超分期的合理折中方案。
要点
- 647例中12.5%(81/647)为SLN阳性N1,术中检出46/81(56.8%)。
- 超分期在术中阴性者中额外发现43.2%(35/81)的N1(宏转移/微转移)。
- 阳性检出率与超分期层面数相关,检查4个层面可检出>90%的N1患者。
核心结论
- SLN超分期可在影像学及术中病理评估均阴性的患者中额外检出43%的N1(宏转移/微转移)。
- 阳性SLN检出率与超分期强度(层面数)相关,检查石蜡块4个层面可检出>90%的N1患者,作者认为这是国际标准超分期的合理折中方案。
研究设计与样本
- SENTIX为国际前瞻性试验(注册号NCT02494063),入组条件为T1a1/LVSI+至T1b2(<4cm,保留生育功能者≤2cm)、常见肿瘤类型、影像学无可疑淋巴结且双侧SLN检出。
- 733例入组患者中647例接受了SLN超分期;SLN术中进行检查,并按强化方案处理(石蜡块按150μm间隔/层面完整切片)。
- 各部位SLN送集中质量控制。
主要发现
- 647例中12.5%(81/647)为淋巴结阳性N1。
- 术中检出转移者占56.8%(46/81),分类为宏转移83.7%、微转移26.3%、孤立肿瘤细胞9.1%。
- 超分期额外发现43.2%(35/81)患者的转移累及:首个层面发现宏转移/微转移20例(24.7%),第2-4层面9例(11.1%),第≥5层面6例(7.4%)。
关键数值与推荐
- SLN超分期采用石蜡块按150μm间隔/层面完整切片的强化方案。
- 检查4个层面可检出>90%的N1患者(原文结论)。
临床怎么用
- 作者认为检查石蜡块4个层面可检出>90%的N1患者,是国际标准超分期的合理折中方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the outcome of SLN staging in the SENTIX international prospective trial of SLN biopsy in patients with cervical cancer with an intensive ultrastaging protocol and central quality control and to evaluate how the intensity of pathological assessment correlates with metastatic detection rate in SLNs. METHODS: Eligible were patients with stages T1a1/LVSI+ to T1b2 (<4 cm, ≤2 cm for fertility sparing), common tumor types, no suspicious lymph nodes on imaging, and bilateral SLN detection. SLNs were examined intraoperatively and processed by an intensive protocol for ultrastaging (paraffin blocks sectioned completely in 150-μm intervals/levels). SLNs from each site were submitted for central quality control. RESULTS: In the SENTIX SLN study, 647 out of 733 enrolled patients underwent SLN ultrastaging, identifying 12.5% (81/647) with node positive, N1 cases. Intraoperative detection revealed metastases in 56.8% (46/81) of these cases, categorized into macrometastases (83.7%), micrometastases (26.3%), and isolated tumor cells (9.1%). Ultrastaging identified additional metastatic involvement in 43.2% (35/81) of patients, with detailed sectioning revealing metastases (MAC/MIC) at first level in 20 cases (24.7%), at levels 2-4 in 9 cases (11.1%), and at level ≥5 in 6 cases (7.4%). CONCLUSION: SLN ultrastaging detects additional 43% of N1 (MAC/MIC) in patients with negative LNs by imaging and intraoperative pathological assessment. The detection rate of positive SLN correlates with the intensity (number of levels) of ultrastaging. Examination of four levels from paraffin blocks, which detects >90% of patients with N1, is a reasonable compromise for an international standard for ultrastaging. STUDY REGISTRATION: NCT02494063 (ClinicalTrials.gov).
引用
- Kocian R, Kohler C, Bajsova S, et al. Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer. Gynecol Oncol. 2024. PMID: 38941963. doi:10.1016/j.ygyno.2024.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。